← FDA DRUG APPROVALS

FDA ANDA · ANDA078712

CIPROFLOXACIN EXTENDED RELEASE

Sponsor: FOSUN PHARMA

APPLICATION
ANDA078712
TYPE
ANDA
ORIGINAL APPROVAL
2007-12-11
LATEST ACTION
2024-09-20
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Discontinued

Products

CIPROFLOXACIN EXTENDED RELEASEDiscontinued
CIPROFLOXACIN 212.6MG, CIPROFLOXACIN HYDROCHLORIDE EQ 287.5MG BASE · TABLET, EXTENDED RELEASE · ORAL

Approval history

2024-09-20Labeling · Supplement 7 · standardAP
2019-05-03Labeling · Supplement 6 · standardAP
2019-04-24Labeling · Supplement 4 · standardAP
2018-10-18Labeling · Supplement 5 · standardAP
2016-07-26Labeling · Supplement 2 · standardAP
2016-07-26Labeling · Supplement 3 · standardAP
2013-12-04Labeling · Supplement 1 · standardAP
2007-12-11OriginalOtherAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →